Abstract
We report a case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis (RA) who received tocilizumab. A 65-year-old woman with a 20-year history of RA participated in a tocilizumab clinical trial. She received a single dose of 8 mg/kg tocilizumab intravenously. The following day the patient started to experience numbness and purpura in all four extremities. The purpura of her left lower limb became necrotic, and a skin ulcer appeared 3 weeks later. Steroid-pulse treatment was initiated 12 weeks after tocilizumab administration, with the result that the numbness improved, and the skin ulcers showed complete epithelialization.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / blood
-
Antibodies, Monoclonal, Humanized
-
Arthritis, Rheumatoid / drug therapy*
-
Blood Platelets / metabolism
-
C-Reactive Protein / metabolism
-
Female
-
Fibrinogen / metabolism
-
Humans
-
Interleukin-6 / blood
-
Necrosis
-
Peripheral Nervous System Diseases / chemically induced*
-
Skin Ulcer / chemically induced*
-
Skin Ulcer / pathology
-
Vascular Endothelial Growth Factor A / blood
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Interleukin-6
-
Vascular Endothelial Growth Factor A
-
Fibrinogen
-
C-Reactive Protein
-
tocilizumab